Pfizer has entered into an agreement to acquire immunotherapy company Coley Pharmaceutical Group, for US$164 M. Based on its Toll-like receptor technology, Coley has developed drug candidates for the treatment of various diseases - including cancer, asthma and allergy, and autoimmune diseases, as well as adjuvants to enhance the effectiveness of vaccines. The article looks at the company's pipeline and previous collaborations, and discusses events at Coley leading up to the deal with Pfizer.